Novavax, Inc. — FY2019 Form 10-K
Business context and reporting period. Novavax is a clinical-stage vaccine developer using recombinant nanoparticle technology and its Matrix-M adjuvant. This annual filing covers the fiscal year ended December 31, 2019; it is not a standalone fourth-quarter report. Its lead programs were NanoFlu, in Phase 3, and ResVax for maternal RSV immunization, also in Phase 3. No vaccine had received regulatory approval or generated product-sales revenue.
Financial performance and liquidity
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Revenue | $18.7 million | $34.3 million | Down $15.6 million, or 46% |
| Research and development | $113.8 million | $173.8 million | Down $60.0 million |
| General and administrative | $34.4 million | $34.4 million | Essentially unchanged |
| Operating loss | $120.6 million | $173.9 million | Improved $53.3 million |
| Net loss | $132.7 million | $184.7 million | Improved $52.1 million |
| Net loss per share | $5.51 | $9.99 | Improved $4.48 |
| Net cash used in operating activities | $136.6 million | $184.8 million | Cash use decreased $48.2 million |
Revenue primarily reflected BMGF grant work and, in 2019, a $7.5 million HHS BARDA contract closeout payment recognized in the fourth quarter. The decline in revenue mainly reflected lower BMGF revenue after Prepare trial enrollment was completed. Lower ResVax development spending and the $9.0 million gain on the Catalent asset sale contributed to the narrower loss. No meaningful product gross margin is reported because Novavax had no commercial product sales.
At December 31, 2019, cash and cash equivalents were $78.8 million, restricted cash was $3.4 million, and total cash, cash equivalents and restricted cash were $82.2 million, versus $82.0 million at the end of 2018. Marketable securities were zero, compared with $22.0 million a year earlier. Working capital was $71.5 million, down from $73.7 million; total assets were $173.0 million and stockholders’ deficit was $186.0 million. The accumulated deficit was $1.43 billion.
Novavax reported $325 million principal amount of 3.75% convertible senior notes due February 1, 2023; the balance-sheet carrying value was $320.6 million. Cash interest paid in 2019 was $12.2 million. Operating lease commitments totaled $17.6 million. The company reported no material off-balance-sheet arrangements.
Material changes, outlook and commentary
- Pipeline: NanoFlu Phase 3 enrollment of 2,652 older adults was completed in October 2019; management expected topline results by the end of Q1 2020. The FDA had acknowledged an accelerated-approval pathway in 2019 and granted Fast Track designation in January 2020. Neither designation assures approval.
- ResVax: The Phase 3 Prepare trial did not meet its primary efficacy endpoint. The filing reports positive secondary and exploratory findings, including fewer RSV-related hospitalizations and reductions in severe hypoxemia and radiographically confirmed pneumonia. FDA and EMA recommended another Phase 3 trial; the company was discussing potential commercial partnerships.
- Restructuring and asset sale: In July 2019, Novavax sold certain manufacturing and development assets to Catalent for $18.0 million plus approximately $0.3 million for supplies, recorded a $9.0 million gain, transferred about 100 employees and assigned two facility leases. Novavax committed to purchase $6.0 million of specified non-commercial manufacturing services through July 2020. The transaction and subsequent attrition reduced headcount by more than 200.
- Other programs: COVID-19 vaccine work was preclinical at year-end; the filing disclosed a $4 million initial CEPI award in March 2020. Ebola development depended on funding or a partner. Other RSV programs were at earlier stages or under evaluation.
- Management outlook: Revenue in 2020 was expected to be significantly below 2019 because Prepare and the HHS BARDA contract had concluded. R&D expense was expected to decrease, partly offset by NanoFlu Phase 3 costs; G&A was expected to remain roughly flat, and capital expenditures to increase slightly.
- Funding: The company said its forecast, including approximately $156 million in net proceeds from Q1 2020 stock sales, supported at least 12 months of planned operations from the filing date. Additional capital would likely be needed; equity issuance could dilute shareholders, while partnerships could require giving up product or technology rights. During 2019, stock sales generated $97.4 million in net proceeds.
Risks, contingencies and unusual items
- Novavax had a long history of losses and expected significant future operating expenses; profitability and future financing were uncertain. The filing warns that inadequate funding could force delays, program cuts or downsizing.
- Clinical, regulatory, manufacturing and commercial outcomes are uncertain. In particular, ResVax missed its primary endpoint and an additional pivotal trial may be needed; NanoFlu still required successful trial results and regulatory review.
- All vaccine manufacturing depended on third parties, creating scale-up, supply, quality and timing risks. Matrix-M also relies on quillaja extract, for which reliable supply is important.
- Debt service and refinancing are risks given the $325 million notes due in 2023 and the company’s operating cash burn. The notes also include repurchase rights following a defined fundamental change.
- Other material risks include competition, intellectual-property disputes, reimbursement and pricing uncertainty, international regulatory changes, and potential dilution from future financings. The company reported no material pending legal proceedings.
- Unusual 2019 items included the $9.0 million Catalent gain and $7.5 million BARDA closeout revenue. The latter was recognized in Q4 2019 and collected in Q1 2020. A 1-for-20 reverse stock split took effect in May 2019; share and per-share figures were retrospectively adjusted.
Important facts for investors to verify
- Whether NanoFlu’s Phase 3 results supported a BLA and whether further FDA requirements affected timing or approval prospects.
- Whether Novavax funded and initiated the additional Phase 3 trial recommended for ResVax, and the terms and progress of any partnership.
- Actual 2020 cash burn, revenue, operating costs and runway versus management’s forecast, including the timing and use of Q1 2020 equity proceeds.
- Any further share issuance and resulting dilution, and the company’s ability to address the 2023 notes and ongoing financing needs.
- Progress in COVID-19 development and CEPI funding, and any material changes to clinical, regulatory, manufacturing or supply risks.